Form 4: Aprea Therapeutics Director Bernd R. Seizinger Reports Acquisition of Shares and Stock Options

Director Bernd R. Seizinger reported the acquisition of common stock and stock options in Aprea Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Bernd R. Seizinger, a director of Aprea Therapeutics, Inc., acquired 1,045 shares of common stock.
• These shares were granted as restricted stock units and will vest on June 20, 2025, contingent upon continued service on the board.
• Seizinger also acquired options to purchase 4,185 shares of common stock at an exercise price of $4.07.
• These options vest fully on June 20, 2025, also contingent upon continued service on the board.
• Following these transactions, Seizinger directly owns 34,730 shares of common stock and options for 4,185 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting conditions tied to continued service align the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their alignment with shareholder interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates